Certain pharmacoeconomic aspects of topical therapy in clinical mycology

The issue of comparing efficacy and safety of original and generic drugs has already quite a deep history. On the one hand, generic drugs are cheaper and more accessible, and production of those most often has been already localized in our country, which makes it possible to ensure import substitution and pharmacological independence of market fluctuations. This is definitely important, but sometimes questions arise about the quality of the drugs reproduced and the thesis that “cheap treatment can be high-priced” is sometimes discussed in almost all countries. Some countries even regulate grades of the drugs reproduced. Clinical mycology represents a branch of medical knowledge where generic drugs occupy a fairly large niche. Recently, research in this field was stimulated by the emergence of terbinafine-resistant forms of dermatophytes. We have tried to demonstrate why the original drug remains the most popular and compliant, even in the situation of active competition, on the example of naftifine hydrochloride-based drugs.